The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Weronika Pociej-MarciakIzabella Karska-BastaJoanna Ozog-BaranAgnieszka Kubicka-TrzaskaAgnieszka Filemonowicz-SkoczekBozena Romanowska-DixonPublished in: Klinika oczna (2018)
Our study suggests that eplerenone may provide an alternative treatment of chronic central serous chorioretinopathy, especially in patients with known contraindications to or ineligible for other treatments (for instance, retinal laser photocoagulation). Further randomized controlled trial is required.